Thursday, 4 August 2016

New Report Covers Ulcerative Colitis (UC) Market, 2023

Ulcerative Colitis (UC) - Market Insights, Epidemiology and Market Forecast-2023 ​is a new market research publication announced by Reportstack. This report provides an overview of the disease and global market trends of the Ulcerative Colitis (UC) for the seven major markets i.e. United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. The Report covers the therapeutics market revenue; average cost of therapy, treatment practice and Ulcerative Colitis (UC) forecasted market share for ten years to 2023 segmented by seven major markets. In addition, the report also includes global forecast of epidemiology of Ulcerative Colitis (UC) till 2023.
Key Coverage and Benefits
• Identifying patient populations in the global “Ulcerative Colitis (UC)market to improve product design, pricing, and launch plans.
• Organize sales and marketing efforts by identifying the best opportunities for Ulcerative Colitis (UC) therapeutics in each of the markets covered.
• To understand the future market competition in the global Ulcerative Colitis (UC) therapeutics market and Insightful review of the key market drivers and barriers.
Scope
• Marketed information including available prescription Medicines, its patent and exclusivity details followed by Medicine sales till 2023.
• The Report also covers the detailed global historical and forecasted epidemiological data covering United States, EU5, Japan and rest of the word from 2013-2023.
• It also provides Ulcerative Colitis (UC) for United States, EU5 and Japan from 2013 and forecasted Market to 2023.
Companies Mentioned
Astellas Pharma • Pfizer • Amgen • Wyeth • BioLineRx • Janssen Biotech • Merck & Co • Millennium Pharmaceuticals • Eli Lilly • Gilead Sciences • Celgene Corporation
Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
Reportstack Market Research
###

No comments:

Post a Comment